NCT05507112View on ClinicalTrials.gov

TIME in Immunotherapy Combined With nCRT for Rectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

December 1, 2029

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

PD-1 inhibitor

Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy

DRUG

Capecitabine

Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.

RADIATION

Long-course radiation therapy

45-50 Gy/day, 5 days a week for a total of 5 weeks.

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05507112 - TIME in Immunotherapy Combined With nCRT for Rectal Cancer | Biotech Hunter | Biotech Hunter